Delcath Systems, Inc : DELCATH TO REPORT FOURTH QUARTER AND FULL YEAR 2012 RESULTS ON MARCH 13, 2013

  Delcath Systems, Inc : DELCATH TO REPORT FOURTH QUARTER AND FULL YEAR 2012
                          RESULTS ON MARCH 13, 2013

NEW YORK, February 28, 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today
announced that it will host a conference call and webcast on Wednesday, March
13, 2013 at 4:30 p.m. ET to discuss its financial results for the fourth
quarter and full year 2012 ended December 31, 2012, and provide an update on
recent corporate progress.

The dial-in numbers for the conference call are 877-299-4454 (U.S.
participants) and 617-597-5447 (International participants); both numbers
require passcode     99502530. To access the live webcast, go to the
Events & Presentations page on the Investor Relations section of the Company's
website at http://www.delcath.com/investors/events/.

A taped replay of the call will be available beginning approximately two hours
after the call's conclusion and will be available for seven days. Dial-in
numbers for the replay are 888-286-8010 and 617-801-6888 for U.S. and
International callers, respectively. The replay passcode for both U.S. and
international callers is 41198605. An archived webcast will also be available
at http://www.delcath.com/investors/events/.

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company
focused on oncology. Our proprietary drug/device combination product, the
Delcath Hepatic Delivery System, is designed to administer high dose
chemotherapy and other therapeutic agents to diseased organs or regions of the
body, while controlling the systemic exposure of those agents. The Company's
initial focus is on the treatment of primary and metastatic liver cancers. In
2010, Delcath announced that its randomized Phase 3 clinical trial for
patients with metastatic melanoma in the liver had successfully achieved the
study's primary endpoint of extended hepatic progression-free survival. The
Company also completed a multi-arm Phase 2 trial to treat other liver cancers.
Outside of the United States, our proprietary product to deliver and filter
melphalan hydrochloride is marketed under the trade name Delcath Hepatic
CHEMOSAT^® Delivery System (CHEMOSAT Delivery System for Melphalan.) The
Company obtained authorization to affix a CE Mark for the Generation Two
CHEMOSAT Delivery System for Melphalan in April 2012. The right to affix the
CE mark allows the Company to market and sell the CHEMOSAT Delivery System for
Melphalan in Europe. In October 2012, the Company satisfied all of the
requirements to affix the CE Mark to the Hepatic CHEMOSAT Delivery System
device for intra-hepatic arterial delivery and extracorporeal filtration of
doxorubicin hydrochloride injection (CHEMOSAT Delivery System for
Doxorubicin), providing a regulatory pathway for the CHEMOSAT Delivery System
for Doxorubicin for countries in Asia that accept the CE Marking as part of
their national regulatory requirements. The Company has not yet received FDA
approval for commercial sale of its system in the United States. The Company's
NDA has been accepted for filing and substantive review by the FDA. For more
information, please visit the Company's website at www.delcath.com.

Private Securities Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf. This news
release contains forward-looking statements, which are subject to certain
risks and uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences include, but are
not limited to, uncertainties relating to: the outcome of the ODAC meeting,
and the impact, if any, of the advisory panel's recommendation on the FDA's
decision regarding the Company's new drug application (NDA), timing of
completion of the FDA's review of our NDA, the extent to which the FDA may
request additional information or data and our ability to provide the same in
a timely manner, acceptability of the Phase 1, 2 and 3 clinical trial data by
the FDA, FDA approval of the Company's NDA for the treatment of ocular
metastatic melanoma to the liver, adoption, use and resulting sales, if any,
in the United States, adoption, use and resulting sales, if any, for the
CHEMOSAT system to deliver and filter melphalan in the EEA, our ability to
successfully commercialize the chemosaturation system and the potential of the
chemosaturation system as a treatment for patients with primary and metastatic
disease in the liver, market acceptance of the Gen Two CHEMOSAT system and
patient outcomes using the same, approval of the current or future
chemosaturation system for delivery and filtration of melphalan, doxorubicin
or other chemotherapeutic agents for various indications in the US and/or in
foreign markets, actions by the FDA or other foreign regulatory agencies, our
ability to successfully enter into strategic partnership and distribution
arrangements in foreign markets including Australia and key Asian markets and
timing an revenue, if any, of the same, the approval of the Hepatic CHEMOSAT
Delivery System device to deliver and filter doxorubicin in key Asian markets
and patient outcomes using the same, our ability to obtain reimbursement for
the CHEMOSAT system, uncertainties relating to the timing and results of
research and development projects, uncertainties relating to the timing and
results of future clinical trials, and uncertainties regarding our ability to
obtain financial and other resources for any research, development and
commercialization activities. These factors, and others, are discussed from
time to time in our filings with the Securities and Exchange Commission. You
should not place undue reliance on these forward-looking statements, which
speak only as of the date they are made. We undertake no obligation to
publicly update or revise these forward-looking statements to reflect events
or circumstances after the date they are made.



Contact Information:
Investors:                  Financial Media
Gregory Gin/Patty Eisenhaur Chris Gale
EVC Group                  EVC Group
646-445-4801/951-316-0577   646-201-5431

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Delcath Systems, Inc via Thomson Reuters ONE
HUG#1681796